Grifols, S.A. logo

Grifols, S.A.

GRFS

NASDAQHealthcareDrug Manufacturers - General

Previous close

$8.00

+$0.01 · +0.13%

Aug 21, 4:00 PM ET

Pre-market

$7.97

−$0.03 · -0.38%

Aug 24, 4:01 AM ET

GRFS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

90

Deep Value

Momentum

32

Weakening

Sentiment

59

Mixed

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
ES
CEO
Jose Ignacio Abia Buenache
Listed since
Jun 2, 2011
Employees
25,258

Market position

Day range

Current $8.00

52-week range

Current $8.00

Open
$8.06
Previous close
$7.99
Volume
218.38K
0.33× average
Average volume
666.85K
Average daily volume
Market cap
6.77B USD
Beta
1.19
Market reference 1
50-day average
$7.5994
+5.27% above average
200-day average
$8.3215
-3.86% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
13.33B EUR
P/E (TTM)
14.7×
P/B (TTM)
1.21×
P/S (TTM)
0.9×
EV / EBITDA
8.21×
Earnings yield
7.13%
Free cash flow yield
13.87%
Dividend yield
0.84%

Profitability & efficiency

Gross margin
37.23%
Operating margin
16.66%
Net margin
6.09%
Return on equity
7.33%
Return on assets
1.96%
Return on invested capital
5.33%

Financial health

Debt / equity
1.54×
Current ratio
2.51×

Earnings

EPS beat rate
18%
2 beats, 9 misses, 0 met estimates
Average EPS surprise
-22.29%
11 comparable reports
Latest EPS result
0.25
Estimate 0.27 · Miss by 6.96%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.330.260.190.11Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 0.237, estimate 0.23, surprise +3.00%, Beat. Q2 2025, reported May 12, 2025: actual 0.133, estimate 0.149, surprise -10.41%, Miss. Q3 2025, reported Jul 29, 2025: actual 0.19, estimate 0.23, surprise -17.39%, Miss. Q4 2025, reported Nov 4, 2025: actual 0.211, estimate 0.242, surprise -12.78%, Miss. Q1 2026, reported Feb 26, 2026: actual 0.289, estimate 0.29, surprise -0.31%, Miss. Q2 2026, reported May 7, 2026: actual 0.173, estimate 0.161, surprise +7.32%, Beat. Q3 2026, reported Jul 28, 2026: actual 0.251, estimate 0.27, surprise -6.96%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 0.285, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.44B2.25B2.06B1.87BQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 2.06B USD, estimate 2.03B USD, surprise +1.14%, Beat. Q2 2025, reported May 12, 2025: actual 1.99B USD, estimate 1.96B USD, surprise +1.66%, Beat. Q3 2025, reported Jul 29, 2025: actual 2.17B USD, estimate 2.2B USD, surprise -1.21%, Miss. Q4 2025, reported Nov 4, 2025: actual 2.14B USD, estimate 2.15B USD, surprise -0.55%, Miss. Q1 2026, reported Feb 26, 2026: actual 2.34B USD, estimate 2.34B USD, surprise -0.20%, Miss. Q2 2026, reported May 7, 2026: actual 2B USD, estimate 2.03B USD, surprise -1.45%, Miss. Q3 2026, reported Jul 28, 2026: actual 2.13B USD, estimate 2.17B USD, surprise -1.54%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 2.25B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings
Strong buy00%
Buy450%
Hold225%
Sell225%
Strong sell00%

GRFS peers

ETFs holding GRFS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research GRFS

research.disclaimer